

SEP 02 2005

Atty. Dkt. No. 041457-0633

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEApplicants: **Juan Mantelle et al.**Title: **TRANSDERMAL COMPOSITIONS CONTAINING LOW
MOLECULAR WEIGHT DRUGS WHICH ARE LIQUID AT
ROOM TEMPERATURES**Appl. No.: **09/986,945**Filing Date: **11/13/2001**Examiner: **Retford O. Berko**Art Unit: **1618****PRE-APPEAL BRIEF REQUEST FOR REVIEW**

Mail Stop AF
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Applicants' arguments for review in support of the Pre-Appeal Brief Request submitted herewith are set forth below.

REMARKS

The rejection of Claims 1-21 as unpatentable under 35 USC § 103 over the combination of USPN 5,656,286 (Miranda et al.), USPN 5,474,783 (Miranda et al) and USPN 5,230,398 (Horstmann et al.) is presented for review. The omission of one or more essential elements required for a *prima facie* rejection and clear errors in the rejection are outlined below.

A. Lack Of Elements For *Prima Facie* Case

To establish a *prima facie* case of obviousness, three basic criteria must be met. First, the prior art references must teach or suggest all of the claim limitations. Second, there must be some suggestion or motivation, either in the references themselves or in the knowledge generally

Atty. Dkt. No. 041457-0633
Appl. No. 09/986,945

available to one of ordinary skill in the art, to modify the references and combine their teachings. Third, there must be a reasonable expectation of success in achieving the invention. The teaching or suggestion to make the claimed combination and the reasonable expectation of success must both be found in the prior art, not in applicant's disclosure. *In re Vaeck*, 947 F.2d 488, 20 USPQ2d 1438 (Fed. Cir. 1991).

The present case at least lacks motivation to combine the references in the manner asserted and a reasonable expectation that the asserted combination would successfully achieve the present invention. This is apparent from the fact that each of the cited references focuses on a problem different from that addressed by the present invention.

The present invention addresses the tendency of low molecular weight drugs that are liquid at room temperature to plasticize polymer matrices, thereby making it difficult to formulate suitable transdermal patches comprising such drugs. This problem is noted in, for example, EP 0 887 075. The present invention addresses this problem by providing a blend that includes (i) a low molecular weight drug that is liquid at room temperature and (ii) a high shear resistant acrylic-based polymer. This problem is not even addressed by the cited references, which are each directed to solving different problems.

The '286 patent discloses polymer compositions comprising polyvinylpyrrolidone, which compositions are shown to be useful to prevent drug crystallization without affecting the rate of drug delivery. The '783 patent discloses a method of adjusting saturation concentration of a drug in a transdermal polymer composition comprising mixing polymers with different solubility parameters. Finally, the '898 patent discloses a transdermal therapeutic system with a specific arrangement of layers.

While the rejection cherry-picks specific elements of these prior art compositions and combines them in an attempt to arrive at the present invention, there is no motivation in these references or elsewhere that would lead the skilled artisan to choose selected elements from each

Atty. Dkt. No. 041457-0633
Appl. No. 09/986,945

composition and combine them in the manner asserted. This is particularly so because none of the references are directed to the problem addressed by the present invention, but instead are each directed to solving different problems. Where only the present invention teaches the advantages of using high shear resistant acrylic-based polymers in order to address problems observed with low molecular weight drugs, the obviousness rejection is improper and should be withdrawn.

“The mere fact that references can be combined or modified does not render the resultant combination obvious unless the prior art also suggests the desirability of the combination.”

MPEP § 2143.01 (citations omitted). Here, where the claimed references do not teach or suggest the desirability of the claimed combination, the obviousness rejection is improper. See *Ex parte Levingood*, 28 USPQ2d 1300 (BPAI 1993) (reversing an obviousness rejection because the prior art evinced no understanding in the art that would have motivated the skilled artisan to make the claimed invention). Indeed, the references of record are silent on the benefits of using a high shear resistant acrylic-based polymer in combination with drugs which are low molecular weight and liquid at or about room temperatures, as presently claimed. Thus, the rejection stems from impermissible hindsight guided only by the teachings of the instant application, and therefore should be withdrawn.

1. Clear Error In Rejection

At pages 5-6, the Final Office Action asserts that the ‘286 patent discloses the use of polymers “having shear resistance of 100 and above at 8lbs/sq in at 72 degrees F.” As examples, the Office Action lists polymethylacrylate (col. 8, Table 1A), Bio-PSA X-7-4503, and Duro-Tak 80-1196. However, these polymers lack the recited characteristics. The ‘286 patent is silent on the shear resistance of the polymethylacrylate. Bio-PSA X-7-4503 is not acrylic-based but instead is silicone-based. Finally, Duro-Tak 80-1196 has a shear resistance of only about 15 hrs. at 8 lbs. per square inch at 72°F. Thus, the cited polymers do not have the characteristics of the polymers recited in the instant claims, and therefore do not support the obviousness rejection.

Atty. Dkt. No. 041457-0633
Appl. No. 09/986,945

In view of the foregoing and Applicants' other arguments of record, Applicants respectfully urge reconsideration and withdrawal of the §103 rejection, and an early notice of allowability.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicants hereby petition for such extension under 37 C.F.R. § 1.135 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Respectfully submitted,

Date September 2, 2005

By Courtenay C. Brinckerhoff

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 295-4094
Facsimile: (202) 672-5399

Courtenay C. Brinckerhoff
Attorney for Applicants
Registration No. 37,288

Doc Code: AP.PRE.REQ

PTO/SB/33 (07-05)

Approved for use through 10/01/2004. OMB 0651-0002
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PRE-APPEAL BRIEF REQUEST FOR REVIEW

Docket Number (Optional)
041457/0633

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" (37 CFR 1.8(a))

on _____

Signature _____

Typed or printed name _____

Application Number

09/986,945

Filed

November 13, 2001

First Named Inventor

Juan Mantealle et al.

Art Unit

1618

Examiner

Retford O. Berkko


Applicant requests review of the final rejection in the above-identified application. No amendments are being filed with this request.

This request is being filed with a notice of appeal.

The review is requested for the reason(s) stated on the attached sheet(s).

Note: No more than five (5) pages may be provided.

I am the

 applicant/inventor. assignee of record of the entire interest.
See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed.
(Form PTO/SB/96) attorney or agent of record.
Registration number 37,37,288 attorney or agent acting under 37 CFR 1.34.
Registration number if acting under 37 CFR 1.34 _____


Signature

Courtenay C. Brinckerhoff

Typed or printed name

202-295-4094

Telephone number



Date

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required.
Submit multiple forms if more than one signature is required, see below.

*Total of 1 forms are submitted.

This collection of information is required by 35 U.S.C. 132. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11, 1.14 and 41.6. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.